Hepatocellular Carcinoma
Abstract: Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study.

Released: January 26, 2023

Expiration: January 25, 2024

Richard S. Finn
Richard S. Finn, MD

Activity

Progress
1
Course Completed